Polaryx Therapeutics Inc. (NASDAQ: PLYX) shares are up on Tuesday as the company has made significant strides in advancing its clinical programs. The positive movement follows the announcement that ...

PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric ...

PLX-200 is an oral compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. According to the company, gemfibrozil’s ability to cross the blood-brain barrier and its established ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Pluxee is on investors’ radar today Pluxee (ENXTPA:PLX) has drawn fresh ...

Parallax is a simple concept to understand, but as it relates to riflescopes it’s difficult to explain. According to Merriam-Webster, parallax is the apparent displacement or the difference in ...

Parallax Worlds, a startup building hyper-realistic virtual simulations to stress-test robots before deployment, today announced it raised $4 million in a seed round. Developing and deploying robots ...

I’ve spent the past few years trying to understand something that often feels beyond understanding—how artificial intelligence, particularly large language models, actually thinks. Or at least, how ...

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is among the hidden penny stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Protalix BioTherapeutics, Inc ...

Plexium has raised $60.1 million, providing an infusion of cash for the recently slimmed-down protein degrader specialist three years on from its breakout year. The biotech put itself on the map in ...

Protein degradation company Plexium has laid off staff as part of a realignment to support the company’s pipeline, which is mostly preclinical, Fierce Biotech has learned. “Plexium has enacted a plan ...

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript May 9, 2025 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were ...

PARALLAX, the post-production studio behind recent titles like A24’s The Legend of Ochi and Everything Everywhere All at Once, has hired Rebecca Rose Perkins as its new Commercial Executive Producer.